Phase II Trial of Rituximab and 2-Chlorodeoxyadenosine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL).
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2016
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2005 New trial record.